GASTRO-ESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTRO-ESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTRO-ESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTRO-ESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody drug takes on tough cancers
Disease control OngoingThis study tests an experimental drug called AZD7789 in people with advanced lung, stomach, or gastroesophageal cancer that cannot be removed by surgery. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The trial aims to check if the drug …
Matched conditions: GASTRO-ESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Real-World study tracks Nivolumab's impact on advanced stomach and esophageal cancers
Knowledge-focused OngoingThis study looks at how the immunotherapy drug nivolumab is used in routine care for adults with advanced cancers of the esophagus, gastroesophageal junction, or stomach. Researchers will analyze data from a Dutch cancer registry to see how long people live after starting nivolum…
Matched conditions: GASTRO-ESOPHAGEAL JUNCTION ADENOCARCINOMA
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
French study tracks Real-World success of combo therapy for stomach cancer
Knowledge-focused OngoingThis study observes 208 adults in France with advanced or metastatic stomach, esophageal, or gastroesophageal junction cancer who are receiving nivolumab combined with chemotherapy as their first treatment. Researchers will track how long patients live and how their disease progr…
Matched conditions: GASTRO-ESOPHAGEAL JUNCTION ADENOCARCINOMA
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC